Nuvilex, Inc. (OTCMKTS:NVLX) On The Decline

[[tagnumber 0]][[tagnumber 1]]After declining through all of September, Nuvilex, Inc. (OTCMKTS:NVLX) has had a good run throughout most of this month that was fueled by a series of optimistic press releases made by the company.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The announcement that the company has applied for an Orphan Drug Designation for their [[tagnumber 6]]CellinaBox®[[tagnumber 7]] treatment for pancreatic cancer and that they have entered into an agreement with the [[tagnumber 6]]University of Technology in Sydney[[tagnumber 7]] really spiced things up and it seemed like the ticker was headed for the top of the charts despite no deadlines being announced for the former.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This shouldn’t be much of a surprise considering that [[tagnumber 6]]NVLX [[tagnumber 7]]has strong support on investor forums and it also boasts a pretty decent balance sheet that should see them through to mid2015. Here is what the company recorded in their report for the second quarter.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 19]] [[tagnumber 20]]cash: $2.89 million[[tagnumber 21]] [[tagnumber 20]]current assets: $3.06 million[[tagnumber 21]] [[tagnumber 20]]total assets: $8.19 million[[tagnumber 21]] [[tagnumber 20]]current and total liabilities: $371 thousand[[tagnumber 21]] [[tagnumber 20]]revenues since inception: $0[[tagnumber 21]] [[tagnumber 20]]quarterly net loss: $1.58 million[[tagnumber 21]] [[tagnumber 32]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The fact that [[tagnumber 6]]NVLX [[tagnumber 7]]hasn’t generated any revenues since its inception and the significant net loss isn’t shocking considering it’s a development stage biotech company. It is considered a long play as it is in the process of developing its treatment and is making some serious steps in that direction.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]More recently there was a press release made by [[tagnumber 6]]Stock Market Media Group[[tagnumber 7]] (SMMG) on October 29 touting the company and its progress. It is good to note that SMMG was compensated $5 thousand per month for coverage of [[tagnumber 6]]NVLX [[tagnumber 7]]by a third party and a principal at the outlet owns [[tagnumber 6]]200 thousand shares[[tagnumber 7]] of [[tagnumber 6]]NVLX [[tagnumber 7]]stock that have been eligible for sale since April 30, 2014.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Anyway, the press release didn’t manage to reverse the downward direction of [[tagnumber 6]]NVLX [[tagnumber 7]]and the ticker is still slowly sliding down the charts. The drops aren’t significant and [[tagnumber 6]]NVLX [[tagnumber 7]]was sitting at $0.229 after yesterday’s final bell having fallen 2.55% in value on a $236 thousand dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Considering the $162 million market cap of the company and comparing it to other biotech entities with similar progress it might seem a bit high, but the potential is still there. In any case, it is always a good idea to do your due diligence and weigh out the risks before making an investment decision.[[tagnumber 2]]

You may also like...